Mannose binding lectin (MBL) is a plasma protein of the innate immune system with the ability to initiate antimicrobial and inflammatory actions. The importance of MBL in defence against infections and especially sepsis is still debated. This article discusses recent developments in MBL research and explores how MBL may be operating in the setting of sepsis.
We present the case of a nine-year-old child diagnosed with septic shock but no apparent risk factors, who was found to have low serum levels of mannose-binding lectin on immunological assay.
This case suggests that young children with a genetically determined low MBL production are at a higher risk of developing septic shock.